// App-Quantinova.ai

2216 : Combinational strategy targeting B cell malignancy using iPSC engineered CAR-NK (FT596) and CAR-T cell (FT819) platforms with therapeutic antibody to achieve an effective deep and durable response

Researchers

Presenter

  • Jode P. Goodridge

Principal Investigators

  • Ryan Bjordahl

  • Milli Mandal

  • Chia-wei Chang

  • Raedun Clarck

  • Sajid Mahmood

  • Huang Zhu

  • Svetlana Gaidarova

  • Robert Blum

  • Frank Cichocki

  • Hui-ting Hsu

  • Greg Bonello

  • Tom Lee

  • Brian Groff

  • Karl-Johan Mamlberg

  • Bruce Walcheck

  • Jeffrey S. Miller

  • Dan Kaufman

  • Bahram Valamehr

Medical Centers

  • Mirati Therapeutics Inc., San Diego, CA

  • University of California-San Diego, San Diego, CA

  • University of Minnesota, Minneapolis, MN

  • University of Oslo, Oslo, Norway

Locations

  • United States

  • Norway

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Hematological malignancies

  • Lymphomas

Biomarkers

  • Natural Killer cells

  • B-lymphocyte antigen CD20

  • T cell receptor alpha locus

  • T-cell receptor

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • Adaptive

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved